Szczegóły obiektu: PARP Inhibitors in the Treatment of Ovarian Cancer: a review of the latest research

Instytucja dostarczająca:Akademicka Platforma Czasopism

Opis

Tytuł:
PARP Inhibitors in the Treatment of Ovarian Cancer: a review of the latest research
Twórca:
Zuzak, Andrzej Paweł;
Satora, Małgorzata;
Cieślik-Porębska, Magdalena;
Kułak, Krzysztof;
Niewiadomska , Jagoda
Opis:
Introduction Ovarian cancer is a leading cause of cancer mortality globally due to late-stage diagnosis and limited treatment options. PARP inhibitors have shown promise as effective treatments for recurrent and various stages of ovarian cancer. Aim of the Study This study reviews the efficacy and application of PARP inhibitors in ovarian cancer treatment over the past 15 years, focusing on literature from the PubMed database post-2009 and considering FDA and EMA guidelines. Review methods A literature review was conducted using the PubMed database, focusing on studies published after 2009. The review also incorporated recommendations from the FDA and the European Medicines Agency regarding the use of PARP inhibitors in ovarian cancer treatment. Results The findings highlight the substantial impact of PARP inhibitors on ovarian cancer treatment, improving PFS and overall outcomes. Olaparib, niraparib, and rucaparib have become integral to ovarian cancer management, offering effective options for patients with BRCA mutations or homologous recombination deficiencies. These inhibitors have been validated in multiple clinical trials, underscoring their robustness and effectiveness. Combination therapies, such as olaparib with bevacizumab, further enhance therapeutic outcomes, showcasing the potential for synergistic effects. Summary PARP inhibitors represent a significant advancement in ovarian cancer treatment, offering improved survival outcomes for patients with specific genetic profiles. Their integration into standard care protocols underscores their importance and efficacy, providing valuable therapeutic options in the fight against ovarian cancer.
Dostępność obiektu:
Dostęp otwarty
Prawa: https://creativecommons.org/licenses/by-nc-sa/4.0 ;
Prawa autorskie (c) 2025 Andrzej Paweł Zuzak, Małgorzata Satora, Magdalena Cieślik-Porębska, Krzysztof Kułak, Jagoda Niewiadomska
Data:
2025.02.21
Typ:
info:eu-repo/semantics/article;
info:eu-repo/semantics/publishedVersion
Język:
angielski
Źródło:
Journal of Education, Health and Sport; Vol. 78 (2025); 57677;
Journal of Education, Health and Sport; Tom 78 (2025); 57677;
2391-8306
Format:
application/pdf
Wydawca:
Nicolaus Copernicus University, Toruń, Poland
Relacja: https://apcz.umk.pl/JEHS/article/view/57677/41465
Temat i słowa kluczowe:
PARP inhibitors;
ovarian cancer;
ovarian cancer treatment
Identyfikator: https://apcz.umk.pl/JEHS/article/view/57677
Dostawca danych:
Akademicka Platforma Czasopism

Podobne obiekty

PARP Inhibitors in the Treatment of Ovarian Cancer: a review of the latest research

Twórca:Zuzak, Andrzej Paweł | Satora, Małgorzata | Cieślik-Porębska, Magdalena | Kułak, Krzysztof | Niewiadomska , Jagoda

Data:2025.02.21

Rodzaj zawartości:teksty

Results of treatment of cancer patients with peritoneal carcinomatosis

Twórca:Bondar, O. | Rybin, A. | Varabina, A.

Data:2022.05.31

Rodzaj zawartości:teksty

PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature

Data:2025.01.22

Rodzaj zawartości:teksty

A PARP inhibitors in the treatment of breast cancer - A Review of literature

Data:2024.11.21

Rodzaj zawartości:teksty

Synchronous borderline ovarian tumor with endometrioid endometrial carcinoma - from diagnosis to treatment. A Case study

Twórca:Eliza Kolasa, Eliza | Paluch, Alicja | Kułak, Krzysztof

Data:2023.06.21

Rodzaj zawartości:teksty

Przełamywanie oporności wielolekowej nowotworów na poziomie genomu: opracowanie metody zapobiegającej nadekspresji transporterów ABC w komórkach nowotworowych opartej na inhibitorach enzymów remodelujących chromatynę

Twórca:Strachowska, Magdalena

Data:2025.05.26 | 2024 | 2025.06.30

Rodzaj zawartości:teksty

Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells, Sonata Bis 2019/34/E/NZ7/00056, Sonata Bis-9 (dataset)

Twórca:Rogalska, Aneta

Data:2024.03.07 | 2023

Rodzaj zawartości:teksty

Endometriosis and ovarian cancer - what they have in common?

Data:2020.08.17

Rodzaj zawartości:teksty

Federacja Bibliotek Cyfrowych

Szczegóły obiektu: PARP Inhibitors in the Treatment of Ovarian Cancer: a review of the latest research

Opis

Podobne obiekty